Reduced premedication
PreclinicalSmall molecule
Reduced premedication is one of 9 small molecule programs targeting Gynecologic Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Gynecologic Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Paraplatin
AAvyxa
Phase 2
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Phase 2
Defactinib
VVerastem, Inc.
Phase 2
SSGJ-707
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
CD70 CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 1
Paclitaxel and Carboplatin
Bristol-Myers SquibbPreclinical
Reduced premedication
SSeoul National University Hospital
Preclinical
Standard Premedication
SSeoul National University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reduced premedication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details